ARCHIVES

Phase III Trial of Imbruvica Halted, Following Increases in Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 1 | January 31, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Finds Physician Recommendation Drives Patient Demand For ABMT

July 19, 1996

Final stats On FY92 Budget; Success Rate Was 35 Percent

December 4, 1992

Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months

June 27, 2014

In Brief: O’Conor Names NCI Liaison To IARC, Saunders Acting IA Director Susan Sieber DCCP Deputy

May 27, 1983

In Brief: NIEHS to Observe20th Anniversary Dec. 3-5 With Scientific Presentations, Big Celebration

November 21, 1986

In Brief: Stetten’s Deputy, Von Euler, Takes Over At NIGMS; Sherman’s Replacement Probably Will Be In-House

March 15, 1974